
Nuntius Therapeutics
Nuntius Therapeutics is a YC Winter 2021 (W21) company. Based in London, England, United Kingdom. Team of 2.
About Nuntius Therapeutics
Summary
Nuntius Therapeutics develops mRNA therapies for patients with cancer, lung disease, and neurodegeneration. Its core technology is a proprietary nanocarrier delivery platform that targets specific tissues and cell types beyond the liver, paired with machine learning models that screen carrier candidates and nucleic acid engineering that boosts protein expression. The platform replaces trial-and-error delivery development and overcomes the cell-targeting limits of current mRNA therapeutics.
Go-to-market
Nuntius Therapeutics partners with pharmaceutical companies to co-develop mRNA therapies, as shown by its collaboration with Taiho Pharmaceutical on cancer applications.
From the Y Combinator listing
Cell-specific genetic medicines
Facts
- Healthcare / Healthcare -> Therapeutics
- London, England, United Kingdom
- 2
- Active
- Early
Founders (2)
- Albert Kwok
- Benita Nagel
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works